| Medical Policy |
Revision |
| Eptinezumab-jjmr (Vyepti™) "Notification" |
Added to initial criteria the requirement of trial and failure of fremanezumab (Ajovy) in addition to erenumab (Aimovig) and galcanezumab (Emgality). Policy notification given 12/17/2021 for effective date 2/15/2022. |
| Injectable and Healthcare Administered Oncology Drugs "Notification" |
Original medical policy criteria issued. Policy notification given 12/17/2021 for effective date 2/15/2022. |
| Trilaciclib (Cosela™) "Notification" |
Added maximum units; medical policy formatting change. Policy notification given 12/17/2021 for effective date 2/15/2022. |
| White Blood Cell Growth Factors "Notification" |
Added requirement of NCCN 2A or higher evidence rating for supporting compendia. Adjusted chemotherapy risk category definitions corresponding to use of WBC GFs for primary prophylaxis of febrile neutropenia. Added maximum units; medical policy formatting change. Policy notification given 12/17/2021 for effective date 2/15/2022. |
Blue Connect